Structure Therapeutics Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 26-May 4:05 PM ET)
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Globe Newswire (Thu, 7-May 4:05 PM ET)
Globe Newswire (Mon, 27-Apr 4:05 PM ET)
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
Globe Newswire (Tue, 14-Apr 4:05 PM ET)
Market Chameleon (Mon, 16-Mar 7:45 AM ET)
Market Chameleon (Mon, 16-Mar 3:30 AM ET)
Globe Newswire (Mon, 16-Mar 7:00 AM ET)
Market Chameleon (Mon, 8-Dec 5:28 AM ET)
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Structure Therapeutics - American Depositary Shares trades on the NASDAQ stock market under the symbol GPCR.
As of June 3, 2026, GPCR stock price declined to $37.13 with 271,126 million shares trading.
GPCR has a beta of -0.18, meaning it tends to be less sensitive to market movements. GPCR has a correlation of 0.00 to the broad based SPY ETF.
GPCR has a market cap of $2.64 billion. This is considered a Mid Cap stock.
Last quarter Structure Therapeutics - American Depositary Shares reported $0 in Revenue and -$.35 earnings per share. This fell short of revenue expectation by $-11 million and missed earnings estimates by -$.02.
In the last 3 years, GPCR traded as high as $94.90 and as low as $13.22.
The top ETF exchange traded funds that GPCR belongs to (by Net Assets): IBB, FDG, SBIO, FFSM, EWX.
GPCR has outperformed the market in the last year with a price return of +70.4% while the SPY ETF gained +28.7%. However, in the short term, GPCR had mixed performance relative to the market. It has underperformed in the last 3 months, returning -41.0% vs +10.3% return in SPY. But in the last 2 weeks, GPCR shares have fared better than the market returning +3.5% compared to SPY +2.9%.
GPCR support price is $35.89 and resistance is $38.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GPCR shares will trade within this expected range on the day.